Zacks Investment Research downgraded shares of ITUS (NYSE:ANIX) from a hold rating to a sell rating in a research report report published on Friday morning, Zacks.com reports.

According to Zacks, “Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States. “

ITUS stock opened at $4.18 on Friday. ITUS has a fifty-two week low of $2.96 and a fifty-two week high of $6.86.

About ITUS

Anixa Biosciences, Inc engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body’s immunological response to the presence of a malignancy.

Featured Article: Real Estate Investment Trust (REIT) ETF

Get a free copy of the Zacks research report on ITUS (ANIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ITUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITUS and related companies with MarketBeat.com's FREE daily email newsletter.